Compare McCormick & Company, Incorporated (MKC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Zimmer Biomet Holdings Inc — how do they compare? McCormick & Company, Incorporated trades at $51.5 (market cap $13.90B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and McCormick & Company, Incorporated pays the higher dividend (3.73%). Which is the better fit depends on your goals.
| MKC | ZBH | |
|---|---|---|
Market Cap | $13.90B | $18.05B |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $104.26 |
52-Week Low | $45.60 | $79.58 |
Enterprise Value | $18.50B | $25.11B |
Dividend Yield | 3.73% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $51.90, down 0.35% with a bearish technical signal. The stock shows strong fundamentals with a low P/E of 8.64, robust 21.91% net margin, and consistent revenue growth to $6.84B in 2025. Recent Q1 2026 earnings beat expectations, while analyst consensus is mixed with 36.67% buy ratings. The pending Unilever merger and upcoming Q3 2026 earnings on October 1, 2026, are key catalysts.
MKC presents a value opportunity with attractive valuation metrics and solid profitability, though technical indicators suggest near-term pressure. The Unilever deal integration and margin expansion potential support long-term growth, but execution risks and competitive pressures remain concerns. Current price sits near the analyst low target of $52.00, offering limited downside protection.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
